Full Press Release Details
HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 14, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the recently completed Phase 2 Study of NurOwn® in Patients with ALS on Monday, July 18, 2016. The Company will host a conference call and webcast with slides at 10:00am Eastern Time.
BrainStorm Cell Therapeutics
| Monday, July 18, 2016 @ 10:00am Eastern Time | |
| Toll Free: | 888-452-4023 |
| Israel Investors: | 1 80 924 5906 |
| International: | 719-457-1512 |
| Conference ID: | 5455376 |
| Webcast: | http://public.viavid.com/index.php?id=120422 |
| Replays, available through August 1, 2016 | |
| Toll Free: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 5455376 |
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn®technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn®has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
LifeSci Advisors, LLC
SOURCE BrainStorm Cell Therapeutics Inc.
Related Links
21 %
more press release views with